OptimizeRx Corp Quarterly Debt-to-equity in % from Q3 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
OptimizeRx Corp quarterly Debt-to-equity history and growth rate from Q3 2019 to Q3 2024.
  • OptimizeRx Corp Debt-to-equity for the quarter ending September 30, 2024 was 44 %, a 617% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 44 +37.9 +617% Sep 30, 2024
Q2 2024 35 +29.4 +518% Jun 30, 2024
Q1 2024 25.8 +20.2 +359% Mar 31, 2024
Q4 2023 16.1 +10.7 +198% Dec 31, 2023
Q3 2023 6.14 +0.58 +10.4% Sep 30, 2023
Q2 2023 5.67 -0.21 -3.57% Jun 30, 2023
Q1 2023 5.61 -0.51 -8.33% Mar 31, 2023
Q4 2022 5.41 -0.55 -9.22% Dec 31, 2022
Q3 2022 5.56 -1.73 -23.7% Sep 30, 2022
Q2 2022 5.88 -3.3 -35.9% Jun 30, 2022
Q1 2022 6.12 -8.04 -56.8% Mar 31, 2022
Q4 2021 5.97 -18 -75.1% Dec 31, 2021
Q3 2021 7.29 -18.1 -71.3% Sep 30, 2021
Q2 2021 9.18 -16.4 -64.2% Jun 30, 2021
Q1 2021 14.2 -8.88 -38.5% Mar 31, 2021
Q4 2020 23.9 +1.72 +7.74% Dec 31, 2020
Q3 2020 25.4 +2.63 +11.5% Sep 30, 2020
Q2 2020 25.6 Jun 30, 2020
Q1 2020 23.1 Mar 31, 2020
Q4 2019 22.2 Dec 31, 2019
Q3 2019 22.8 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.